BioTrack Capital
博远资本
BioTrack Capital (博远资本) is a China-based healthcare-focused investment fund. Per 5Y Capital's 2025 and 2026 deal announcements, it has participated as a co-lead or co-investor in several biotech financings, including DeepKinase's Series A in 2023 alongside Longpan Investment, Minghui Pharma's $131 million pre-IPO round in 2025, and Syneron Bio's $150 million Series B in early 2026 . The fund also appears in earlier FreeS Capital coverage from 2021–2023 as a follow-on investor in companies such as OnQuality Pharmaceuticals and Yanming Biotech, typically alongside institutions like FreeS, Matrix Partners China, and Lilly Asia Ventures . Elsewhere's corpus does not contain additional detail on its founding, team, or fund size.
AI-generated — may contain errors, please verify.
Coverage
5Y News | Xunming Life Sciences Closes Tens of Millions of Dollars in Series A+ Funding
Accelerating the construction of next-generation Tech-Bio agent infrastructure.
5Y News | Syneron Bio Closes $150 Million Series B Round
Syneron Bio today announced the completion of its Series B funding round.
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
From Angel to G+ Round: 5 Early-Stage FreeS Fund Portfolio Companies Raise Over 3 Billion RMB | FreeS Family Funding News · Vol 14
Looking forward to working alongside more outstanding founders.
Qitan Tech Closes RMB 700 Million Series C Round to Advance Commercialization of Domestic Nanopore Sequencing Technology
Breaking Through the "Mass-Production No-Man's-Land" of Domestic Nanopore Sequencing
FreeS Family Funding News · July | PatPat, Yanming Biotech, Qbit, and Innostar Secure Financing
We've also released three short videos this issue — follow us to check them out.
FreeS Family Funding News · April | OnKure Therapeutics, IceKredit, Duanyu Liangjin, and Jiuzhou Yunjian Secure Funding
New Column Launch
